Citius Pharmaceuticals (CTXR) Projected to Post Quarterly Earnings on Friday

Citius Pharmaceuticals (NASDAQ:CTXR) is expected to be announcing its Q4 2025 results before the market opens on Friday, December 26th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, December 23, 2025 at 7:00 AM ET.

Citius Pharmaceuticals Stock Down 1.0%

CTXR opened at $1.04 on Wednesday. The stock’s 50 day moving average price is $1.28 and its two-hundred day moving average price is $1.32. The firm has a market capitalization of $17.69 million, a P/E ratio of -0.31 and a beta of 1.51. Citius Pharmaceuticals has a 12-month low of $0.65 and a 12-month high of $5.95.

Wall Street Analyst Weigh In

CTXR has been the topic of several research analyst reports. Wall Street Zen downgraded shares of Citius Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, September 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Monday. Finally, D. Boral Capital restated a “buy” rating and set a $6.00 price objective on shares of Citius Pharmaceuticals in a report on Thursday, December 4th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Citius Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $6.00.

Hedge Funds Weigh In On Citius Pharmaceuticals

An institutional investor recently bought a new position in Citius Pharmaceuticals stock. XTX Topco Ltd purchased a new stake in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 20,146 shares of the company’s stock, valued at approximately $32,000. XTX Topco Ltd owned approximately 0.19% of Citius Pharmaceuticals at the end of the most recent reporting period. 16.88% of the stock is currently owned by institutional investors and hedge funds.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.